Ignite Creation Date:
2025-12-24 @ 2:07 PM
Ignite Modification Date:
2026-02-20 @ 7:29 PM
Study NCT ID:
NCT07001995
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-06-03
First Post:
2025-05-25
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression
Sponsor:
Hunan Province Tumor Hospital
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
CALLISTO
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None